Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion-Positive Pancreatic Adenocarcinoma: A Case Report

Article Tools CASE REPORTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/PO.22.00467 JCO Precision Oncology no. 7 (2023) e2200467. Published online April 20, 2023. PMID: 37079858 Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion–Positive Pancreatic Adenocarcinoma: A Case Report Theresa Reutter, MD1xTheresa ReutterSearch for articles by this author; Jana Fassunke , PhD2xJana FassunkeSearch for articles by this author; Michael Püsken , MD3xMichael PüskenSearch for articles by this author; Jan-Phillip Weber, MD1xJan-Phillip WeberSearch for articles by this author; Elke Binot2xElke BinotSearch for articles by this author; Anna Eisert, MD1xAnna EisertSearch for articles by this author; Rieke Fischer , MD1xRieke FischerSearch for articles by this author; Lucia Nogova , MD1xLucia NogovaSearch for articles by this author; Richard Riedel, MD1xRichard RiedelSearch for articles by this author; Diana Schaufler, MD1xDiana SchauflerSearch for articles by this author; Heather Scharpenseel, MD1xHeather ScharpenseelSearch for articles by this author; Matthias Scheffler , MD1xMatthias SchefflerSearch for articles by this author; Holger Schulz, MD4xHolger SchulzSearch for articles by this author; Dirk‐Thomas Waldschmidt, MD5xDirk‐Thomas WaldschmidtSearch for articles by this author; Thomas Zander , MD1xThomas ZanderSearch for articles by this author; Sabine Merkelbach-Bruse, PhD2xSabine Merkelbach-BruseSearch for articles by this author; Peter Schirmacher, MD6xPeter SchirmacherSearch for articles by this author; Reinhard Büttner , MD2xReinhard BüttnerSearch for articles by this author; Jürgen Wolf , MD1xJürgen WolfSearch for articles by this author; and Sebastian Michels , MD1xSebastian MichelsSearch for articles by this author Show More 1Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Cologne, Germany2Department of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany3Faculty of Medicine and University Hospital Cologne, Institute for Diagnostic and Interventional Radiology, University of Cologne, Cologne, Germany4Practice for Clinical Hematology and Oncology, Frechen, Germany5Department of Gastroenterology and Hepatology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany6Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany https://doi.org/10.1200/PO.22.00467 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyAUTHOR CONTRIBUTIONSConception and design: Theresa Reutter, Anna Eisert, Diana Schaufler, Matthias Scheffler, Thomas Zander, Sebastian MichelsAdministrative support: Theresa Reutter, Anna Eisert, Peter Schirmacher, Sebastian MichelsProvision of study materials or patients: Theresa Reutter, Jana Fassunke, Elke Binot, Heather Scharpenseel, Holger Schulz, Thomas Zander, Peter Schirmacher, Sebastian MichelsCollection and assembly of data: Theresa Reutter, Jan-Phillip Weber, Elke Binot, Anna Eisert, Rieke Fischer, Lucia Nogova, Diana Schaufler, Heather Scharpenseel, Matthias Scheffler, Holger Schulz, Thomas Zander, Peter Schirmacher, Sebastian MichelsData analysis and interpretation: Theresa Reutter, Jana Fassunke, Anna Eisert, Richard Riedel, Diana Schaufler, Sabine Merkelbach-Bruse, Peter Schirmacher, Sebastian MichelsManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Jana FassunkeHonoraria: AstraZenecaMichael PüskenConsulting or Advisory Role: Bayer/VitalSpeakers' Bureau: BD BardAnna EisertConsulting or Advisory Role: MERCK, Amgen, AstraZeneca/MedImmuneRieke FischerConsulting or Advisory Role: Bristol Myers Squibb/MedarexResearch Funding: Bristol Myers Squibb (Inst)Travel, Accommodations, Expenses: JanssenLucia NogovaHonoraria: Pfizer, Celgene, Novartis, Roche, Boehringer Ingelheim, Bristol Myers Squibb, Takeda, Bayer, Janssen, AstraZenecaConsulting or Advisory Role: Novartis, Boehringer Ingelheim, Bristol Myers Squibb, Roche, Janssen, Pfizer, Takeda, Bayer, AstraZenecaResearch Funding: Pfizer (Inst), Bristol Myers Squibb (Inst), Novartis (Inst), MSD (Inst), Janssen (Inst), Amgen (Inst), Dracen (Inst)Travel, Accommodations, Expenses: Novartis, Pfizer, Celgene, Boehringer Ingelheim, JanssenRichard RiedelConsulting or Advisory Role: Boehringer Ingelheim, NovartisTravel, Accommodations, Expenses: Lilly, LoxoMatthias SchefflerHonoraria: Boehringer Ingelheim, Takeda, Roche, Amgen, Pfizer, AstraZeneca/Daiichi Sankyo, Siemens Healthineers, NovartisConsulting or Advisory Role: Boehringer Ingelheim, Takeda, Roche, Amgen, Janssen Oncology, Novartis, Pfizer, Sanofi/AventisResearch Funding: Amgen (Inst), Janssen (Inst), Novartis (Inst), BMS GmbH & Co. KG (Inst), Dracen (Inst), Siemens Healthineers (Inst)Travel, Accommodations, Expenses: Boehringer Ingelheim, Janssen, Amgen, PfizerDirk-Thomas WaldschmidtSpeakers' Bureau: AstraZeneca, Eisai Germany, Incyte, Roche Pharma AG, SERVIER, MSD Oncology, Ipsen, Bayer/VitalTravel, Accommodations, Expenses: AstraZeneca, Lilly, SERVIER, IpsenThomas ZanderConsulting or Advisory Role: Roche, Pfizer, BMS, MSD Oncology, NovartisSabine Merkelbach-BruseHonoraria: AstraZeneca, Bristol Myers Squibb, Novartis, Pfizer, Roche Pharma AG, Amgen, JanssenConsulting or Advisory Role: Bristol Myers Squibb, Novartis, AstraZenecaPeter SchirmacherHonoraria: Incyte, Eisai Germany, MSD Oncology, BMSConsulting or Advisory Role: Bristol Myers Squibb, MSD, Novartis, Roche, Incyte, Eisai GermanySpeakers' Bureau: Incyte, BMS GmbH & Co. KGResearch Funding: Novartis (Inst), Roche (Inst), Bristol Myers Squibb (Inst)Reinhard BüttnerStock and Other Ownership Interests: Gnothis IncHonoraria: AstraZeneca, AbbVie, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Merck Serono, MSD, Novartis, Qiagen, Pfizer, Roche, IlluminaResearch Funding: Roche (Inst)Jürgen WolfHonoraria: AbbVie, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, MSD, Novartis, Roche, Amgen, Bayer, Blueprint Medicines, Chugai Pharma Europe, Daiichi Sankyo Europe GmbH, Ignyta, Janssen, Lilly, Loxo, Loxo/Lilly, Pfizer, Seattle Genetics, Takeda, Nuvalent, IncConsulting or Advisory Role: AbbVie, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Chugai Pharma, Ignyta, Lilly, MSD Oncology, Novartis, Pfizer, Roche, Janssen, Loxo/Lilly, Blueprint Medicines, Amgen, Takeda, Bayer, Daiichi Sankyo Europe GmbH, Seattle Genetics, Nuvalent, IncResearch Funding: Bristol Myers Squibb, Novartis, Pfizer, JanssenTravel, Accommodations, Expenses: Norvatis, Janssen, Takeda, Pfizer, Boehringer IngelheimSebastian MichelsHonoraria: Novartis, Pfizer, AstraZeneca, Janssen Oncology, Takeda, Merck KGaAConsulting or Advisory Role: Boehringer Ingelheim, Pfizer, Roche Pharma AGResearch Funding: Pfizer (Inst), Novartis (Inst), Bristol Myers Squibb (Inst)Travel, Accommodations, Expenses: NovartisNo other potential conflicts of interest were reported.